Table 3.
BG cohort (events/patients 162/1,122) | TG cohort (events/patients 253/1,826) | ||||
---|---|---|---|---|---|
HR (95% CI) | P‐value | HR (95% CI) | P‐value | ||
Model 1 | Model 2 | ||||
2h‐BG (1 SD; mmol/L) | 1.34 (1.08–1.67) | 0.009 | ppTG † (1 SD; mmol/L) | 1.24 (1.06–1.45) | 0.008 |
Model 3 | Model 4 | ||||
2h‐BG (1 SD; mmol/L) | 1.34 (1.07–1.68) | 0.010 | ppTG † (1 SD; mmol/L) | 1.18 (1.00–1.39) | 0.045 |
Models 1 and 2 were adjusted for age, sex, diabetes duration, body mass index, systolic blood pressure, HbA1c levels, total cholesterol levels, high‐density lipoprotein cholesterol levels, current smoking, alcohol intake, history of cardiovascular disease and history of cancer.
Models 3 and 4 were adjusted for the use of oral antidiabetic drugs, insulin, antihypertensive agents and agents for dyslipidemia in addition to the covariates included in models 1 and 2.
Ln‐transformed. 2h‐BG, 2‐h post‐breakfast blood glucose; ppTG, postprandial serum triglyceride; SD, standard deviation.